Literature DB >> 11554592

Factor VIII inhibitors.

P Lollar1, J F Healey, R T Barrow, E T Parker.   

Abstract

Mesh：

Substances：

Year:  2001        PMID： 11554592     DOI： 10.1007/978-1-4615-1277-6_6

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN： 0065-2598            Impact factor:   2.622


× No keyword cloud information.
  15 in total

1.  Effect of Biophysical Properties of Phosphatidylserine Particle on Immune Tolerance Induction Toward Factor VIII in a Hemophilia A Mouse Model.

Authors:  Radha Ramakrishnan; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2016-07-16       Impact factor: 3.534

2.  Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice.

Authors:  Vivek S Purohit; C Russell Middaugh; Sathyamangalam V Balasubramanian
Journal:  J Pharm Sci       Date:  2006-02       Impact factor: 3.534

3.  Interaction of dicaproyl phosphatidylserine with recombinant factor VIII and its impact on immunogenicity.

Authors:  Vivek S Purohit; Sathyamangalam V Balasubramanian
Journal:  AAPS J       Date:  2006-05-26       Impact factor: 4.009

4.  Phosphatidylserine reduces immune response against human recombinant Factor VIII in Hemophilia A mice by regulation of dendritic cell function.

Authors:  Puneet Gaitonde; Aaron Peng; Robert M Straubinger; Richard B Bankert; Sathy V Balu-Iyer
Journal:  Clin Immunol       Date:  2010-11-20       Impact factor: 3.969

5.  Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex.

Authors:  Vivek S Purohit; Karthik Ramani; Rita Sarkar; Haig H Kazazian; Sathyamangalam V Balasubramanian
Journal:  J Biol Chem       Date:  2005-02-23       Impact factor: 5.157

6.  Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice.

Authors:  Krithika A Shetty; Matthew P Kosloski; Donald E Mager; Sathy V Balu-Iyer
Journal:  Biopharm Drug Dispos       Date:  2016-09-13       Impact factor: 1.627

7.  Subcutaneous administration of Lyso-phosphatidylserine nanoparticles induces immunological tolerance towards Factor VIII in a Hemophilia A mouse model.

Authors:  Fiona Y Glassman; Sathy V Balu-Iyer
Journal:  Int J Pharm       Date:  2018-07-05       Impact factor: 5.875

8.  Immunogenicity and pharmacokinetic studies of recombinant factor VIII containing lipid cochleates.

Authors:  Matthew P Kosloski; Aaron Peng; Prashant R Varma; Anas M Fathallah; Razvan D Miclea; Donald E Mager; Sathy V Balu-iyer
Journal:  Drug Deliv       Date:  2010-11-30       Impact factor: 6.419

9.  Effect of route of administration of human recombinant factor VIII on its immunogenicity in Hemophilia A mice.

Authors:  Aaron Peng; Puneet Gaitonde; Matthew P Kosloski; Razvan D Miclea; Prashant Varma; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2009-12       Impact factor: 3.534

Review 10.  Engineering less immunogenic and antigenic FVIII proteins.

Authors:  Kathleen P Pratt
Journal:  Cell Immunol       Date:  2015-11-02       Impact factor: 4.868
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.